Bristol-Myers Squibb and Allied Minds announced today the formation of a joint research institute to foster the research and development of pharmaceutical compounds.
The company, Allied-Bristol Life Sciences, is a joint operation that will work together with academic research institutions to screen and identify potential therapeutic candidates for the market.
The program will allow university researchers access to Bristol’s drug research database in exchange for the screening of potential therapeutic candidates and the performance of pre-clinical studies.
Such partnerships often exist between pharmaceutical companies and academic institutions.
Joint endeavor between Bristol and AlliedMind sets the stage for a new approach to preclinical pharmaceutical development.
Report: Partnering Agreements with Bristol-Myers Squibb 2009-2014
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity